Any feedback?
Please rate this page
(search_result.php)
(0/150)

BRENDA support

Refine search

Search Application

show results
Don't show organism specific information (fast!)
Search organism in taxonomic tree (slow, choose "exact" as search mode, e.g. "mammalia" for rat,human,monkey,...)
(Not possible to combine with the first option)
Refine your search

Search term: drug development

Results 1 - 100 of 1463 > >>
EC Number Recommended Name Application Commentary
Display the word mapDisplay the reaction diagram Show all sequences 3.5.2.B2(+)-gamma-lactamase drug development application of the enzyme in antiviral drug synthesis. The enzyme catalyzes the specific hydrolysis of (+)-gamma-lactam out of the racemic gamma-lactam (2-azabicyclo[2.2.1]hept-5-en-3-one) to leave optically pure (-)-gamma-lactam, which is the key building block of antiviral drugs such as carbovir and abacavir
Display the word mapDisplay the reaction diagram Show all sequences 3.5.2.B2(+)-gamma-lactamase drug development the enzyme can be a promising candidate of biocatalyst for industrial applications of highly valuable chiral pharmaceutical chemicals
Display the word mapDisplay the reaction diagram Show all sequences 3.5.2.B2(+)-gamma-lactamase drug development the enzyme is an ideal catalyst for the preparation of carbocyclic nucleosides of pharmaceutical interest. IT can be used in a scalable bioprocess and is an efficient, economical, and environmentally route for producing optically pure (-)-gamma-lactam
Display the word mapDisplay the reaction diagram Show all sequences 3.5.2.B2(+)-gamma-lactamase drug development the use of gamma-lactamase as a biocatalyst offers an attractive and environmentally friendly approach for the synthesis of a broad range of carbocyclic nucleoside drugs. The enzyme can be used for enzymatic kinetic resolution of racemic Vince lactam (2-azabicyclo[2.2.1]hept-5-en-3-one) in the industry. Optically pure enantiomers and their hydrolytic products are widely employed as key chemical intermediates for developing a wide range of carbocyclic nucleoside medicines, including US FDA-approved drugs peramivir and abacavir
Display the reaction diagram Show all sequences 1.14.14.167(13S,14R)-13-O-acetyl-1-hydroxy-N-methylcanadine 8-hydroxylase drug development reconstitute of the noscapine gene cluster in Saccharomyces cerevisiae to achieve the microbial production of noscapine and related pathway intermediates
Show all pathways known for 2.5.1.10Display the word mapDisplay the reaction diagram Show all sequences 2.5.1.10(2E,6E)-farnesyl diphosphate synthase drug development the discovery of new binding sites and non-bisphosphonate binders is a critical step towards the investigation of farnesyl pyrophosphate synthase as a drug target for human African trypanosomiasis and opens up the possibility of a fragment-to-lead optimisation program
Display the word mapDisplay the reaction diagram Show all sequences 2.5.1.92(2Z,6Z)-farnesyl diphosphate synthase drug development the enzyme possibly represents an attractive drug target for the development of selective inhibitors aiming the erythrocytic stages of Plasmodium falciparum and development of more potent bisphosphonate-based inhibitors selectivity targeting this key point of the plasmodial isoprenoid metabolism
Display the word mapDisplay the reaction diagram Show all sequences 2.3.2.24(E3-independent) E2 ubiquitin-conjugating enzyme drug development E2 ubiquitin-conjugating enzymes might be potential drug targets, potential strategies for drug discovery targeting UBE2O, overview
Display the word mapDisplay the reaction diagram Show all sequences 4.2.3.20(R)-limonene synthase drug development D-limonene is effective in cancer prevention in animal cancer models, some clinical applications have been performed
Show all pathways known for 1.1.3.15Display the word mapDisplay the reaction diagram Show all sequences 1.1.3.15(S)-2-hydroxy-acid oxidase drug development in humans the enzyme is a potential drug target for treatment of primary hyperoxaluria, a genetic disorder where overproduction of oxalate results in the formation of kidney stones
Show all pathways known for 1.1.3.15Display the word mapDisplay the reaction diagram Show all sequences 1.1.3.15(S)-2-hydroxy-acid oxidase drug development isozyme Hao2 is a target for drug development in high blood pressure
Display the word mapDisplay the reaction diagram Show all sequences 4.1.2.47(S)-hydroxynitrile lyase drug development industrial processes
Show all pathways known for 2.4.1.18Display the word mapDisplay the reaction diagram Show all sequences 2.4.1.181,4-alpha-glucan branching enzyme drug development small molecules with diverse scaffolds but similar three-dimensional structures show a similar biological effect. Deriving scaffolds from docking and similarity search is a successful design strategy for difficult targets
Show all pathways known for 4.1.3.36Display the word mapDisplay the reaction diagram Show all sequences 4.1.3.361,4-dihydroxy-2-naphthoyl-CoA synthase drug development the enzyme is a target for development of antibacterial agents
Display the word mapDisplay the reaction diagram Show all sequences 2.3.1.671-alkylglycerophosphocholine O-acetyltransferase drug development identification of LPCAT2-specific inhibitors in order to ameliorate PAF-related inflammatory diseases, fluorescence-based high-throughput library screening
Show all pathways known for 1.1.1.267Display the word mapDisplay the reaction diagram Show all sequences 1.1.1.2671-deoxy-D-xylulose-5-phosphate reductoisomerase drug development the enzyme is a potential target for antimalarial drug development and chemotherapy
Show all pathways known for 1.1.1.267Display the word mapDisplay the reaction diagram Show all sequences 1.1.1.2671-deoxy-D-xylulose-5-phosphate reductoisomerase drug development the enzyme is a target for antibacterial agents and inhibitor design
Show all pathways known for 1.1.1.267Display the word mapDisplay the reaction diagram Show all sequences 1.1.1.2671-deoxy-D-xylulose-5-phosphate reductoisomerase drug development the enzyme is an excellent drug target in a number of pathogenic organisms
Show all pathways known for 1.1.1.267Display the word mapDisplay the reaction diagram Show all sequences 1.1.1.2671-deoxy-D-xylulose-5-phosphate reductoisomerase drug development Escherichia coli Dxr represents a valuable model enzyme for the screening for new antimalarial compounds, since work with the Plasmodium falciparum Dxr is associated with considerably high effort due to the instability of this enzyme and the low yield of the available recombinant expression system, no major differences in the IC50 between Escherichia coli Dxr and Plasmodium falciparum Dxr
Show all pathways known for 1.1.1.267Display the word mapDisplay the reaction diagram Show all sequences 1.1.1.2671-deoxy-D-xylulose-5-phosphate reductoisomerase drug development 1-deoxy-D-xylulose-5-phosphate reductoisomerase in the nonmevalonate isoprene biosynthesis pathway is a target for developing antimalarial drugs
Show all pathways known for 1.1.1.267Display the word mapDisplay the reaction diagram Show all sequences 1.1.1.2671-deoxy-D-xylulose-5-phosphate reductoisomerase drug development because the enzyme is absent in humans, DXR is a target for drug discovery
Show all pathways known for 1.1.1.267Display the word mapDisplay the reaction diagram Show all sequences 1.1.1.2671-deoxy-D-xylulose-5-phosphate reductoisomerase drug development the enzyme is a target for the design of antimalarial drugs
Show all pathways known for 1.1.1.267Display the word mapDisplay the reaction diagram Show all sequences 1.1.1.2671-deoxy-D-xylulose-5-phosphate reductoisomerase drug development enzyme DXR is a validated antimicrobial target
Show all pathways known for 1.1.1.267Display the word mapDisplay the reaction diagram Show all sequences 1.1.1.2671-deoxy-D-xylulose-5-phosphate reductoisomerase drug development enzyme DXR is an antimicrobial target
Show all pathways known for 1.1.1.267Display the word mapDisplay the reaction diagram Show all sequences 1.1.1.2671-deoxy-D-xylulose-5-phosphate reductoisomerase drug development the enzyme from Escherichia coli is a valuable target for the development of antimicrobial compounds
Show all pathways known for 1.1.1.267Display the word mapDisplay the reaction diagram Show all sequences 1.1.1.2671-deoxy-D-xylulose-5-phosphate reductoisomerase drug development the enzyme from Mycobacterium smegmatis is a valuable target for the development of antimicrobial compounds
Show all pathways known for 1.1.1.267Display the word mapDisplay the reaction diagram Show all sequences 1.1.1.2671-deoxy-D-xylulose-5-phosphate reductoisomerase drug development the methyl erythritol phosphate (MEP) pathway represents an attractive series of targets for antibiotic design, considering each enzyme of the pathway is both essential and has no human homologues, including enzymes DXP reductoisomerase (IspC) and MEP cytidylyltransferase (IspD)
Show all pathways known for 2.2.1.7Display the word mapDisplay the reaction diagram Show all sequences 2.2.1.71-deoxy-D-xylulose-5-phosphate synthase drug development DXS is an attractive target for the development of antibiotics, antimalarials, and herbicides
Display the word mapDisplay the reaction diagram Show all sequences 2.7.1.671-phosphatidylinositol 4-kinase drug development type II phosphatidylinositol 4-kinases are promising targets for therapeutic intervention against viral infections, detailed overview
Display the word mapDisplay the reaction diagram Show all sequences 2.7.1.1501-phosphatidylinositol-3-phosphate 5-kinase drug development potential for targeting this kinase in developing small-molecule antivirals against SARS-CoV-2. The infection is fully blocked by bafilomycin A1, which inhibits the vacuolar type H+-ATPase (V-ATPase) acidification activity. Apilimod and vacuolin-1 prevent cytoplasmic entry of VSV-MeGFP-ZEBOV (from Zaire ebolavirus VSV-ZEBOV)
Display the word mapDisplay the reaction diagram Show all sequences 2.7.1.1501-phosphatidylinositol-3-phosphate 5-kinase drug development the enzyme is a potential target for developing small-molecule antivirals against SARS-CoV-2
Display the word mapDisplay the reaction diagram Show all sequences 1.1.1.14611beta-hydroxysteroid dehydrogenase drug development isozyme 11beta-HSD1 is a target in treatment of metabolic diseases such as diabetes mellitus type 2 or obesity
Display the word mapDisplay the reaction diagram Show all sequences 1.1.1.14611beta-hydroxysteroid dehydrogenase drug development 11beta-HSD1 will significantly contribute to the biotransformation of oracin in humans. The microsomal carbonyl reductase has a great potential to significantly impair the chemotherapy with the anticancer drug oracin
Display the word mapDisplay the reaction diagram Show all sequences 1.1.1.B4011beta-hydroxysteroid dehydrogenase (NAD+) drug development the enzyme is a target for inhibitor design and development
Show all pathways known for 1.1.1.141Display the word mapDisplay the reaction diagram Show all sequences 1.1.1.14115-hydroxyprostaglandin dehydrogenase (NAD+) drug development induction of 15-hydroxyprostaglandin dehydrogenase expression or utilization of 15-keto-PGE2 analogue may have therapeutic benefits for the treatment of endotoxin-associated liver inflammation/injury
Display the word mapDisplay the reaction diagram Show all sequences 2.1.1.17916S rRNA (guanine1405-N7)-methyltransferase drug development development of potent agents against 16S-RMTase producers as targets for treatment of multidrug resistant bacteria
Show all pathways known for 1.14.14.32Display the word mapDisplay the reaction diagram Show all sequences 1.14.14.3217alpha-hydroxyprogesterone deacetylase drug development regioisomeric 17beta-N-phenylpyrazolyl steroid derivatives have weak inhibitory effect on 17alpha-hydroxylase/C17,20-lyase
Show all pathways known for 1.14.14.32Display the word mapDisplay the reaction diagram Show all sequences 1.14.14.3217alpha-hydroxyprogesterone deacetylase drug development silencing CYP17 expression may be a strategy for therapy of hyperandrogenism diseases, and also sets an example for the use of RNAi technology in endocrine diseases
Display the word mapDisplay the reaction diagram Show all sequences 1.1.1.6217beta-estradiol 17-dehydrogenase drug development several 17beta-HSD isozymes are targets for drug development with importance in cancer, metabolic diseases, neurodegeneration and possibly immunity
Display the word mapDisplay the reaction diagram Show all sequences 1.1.1.6217beta-estradiol 17-dehydrogenase drug development the enzyme is considered a promising drug target against estrogen-dependent cancers
Display the word mapDisplay the reaction diagram Show all sequences 1.1.1.6217beta-estradiol 17-dehydrogenase drug development the enzyme constitutes an interesting therapeutic target for estrogen-dependent diseases
Display the word mapDisplay the reaction diagram Show all sequences 2.3.1.222-acylglycerol O-acyltransferase drug development [acyl CoA]monoacylglycerol acyltransferase 2 (MGAT2) is of interest as a target for therapeutic treatment of diabetes, obesity and other diseases which together constitute the metabolic syndrome
Show all pathways known for 2.7.6.3Display the word mapDisplay the reaction diagram Show all sequences 2.7.6.32-amino-4-hydroxy-6-hydroxymethyldihydropteridine diphosphokinase drug development the enzyme is a target for antibiotic development
Show all pathways known for 2.7.6.3Display the word mapDisplay the reaction diagram Show all sequences 2.7.6.32-amino-4-hydroxy-6-hydroxymethyldihydropteridine diphosphokinase drug development the enzyme is a target for antimicrobial development
Show all pathways known for 4.6.1.12Display the word mapDisplay the reaction diagram Show all sequences 4.6.1.122-C-methyl-D-erythritol 2,4-cyclodiphosphate synthase drug development framework for the development of IspF inhibitors to generate lead compounds of therapeutic potential against microbial pathogens
Show all pathways known for 2.7.7.60Display the word mapDisplay the reaction diagram Show all sequences 2.7.7.602-C-methyl-D-erythritol 4-phosphate cytidylyltransferase drug development due to the absence of the pathway in mammals enzyme provides a potential target for new antibiotics
Show all pathways known for 2.7.7.60Display the word mapDisplay the reaction diagram Show all sequences 2.7.7.602-C-methyl-D-erythritol 4-phosphate cytidylyltransferase drug development insights in structure and function of MtIspD
Show all pathways known for 2.7.7.60Display the word mapDisplay the reaction diagram Show all sequences 2.7.7.602-C-methyl-D-erythritol 4-phosphate cytidylyltransferase drug development 2-C-methyl-D-erythritol 4-phosphate cytidyltransferase, enzyme IspD, is a potential therapeutic drug target in Plasmodium vivax
Show all pathways known for 2.7.7.60Display the word mapDisplay the reaction diagram Show all sequences 2.7.7.602-C-methyl-D-erythritol 4-phosphate cytidylyltransferase drug development IspD is a druggable target for the development of additional antimalarial agents. 1R,3S-MMV008138 shows promise as a potential scaffold for target-based antimalarial drug development
Show all pathways known for 2.7.7.60Display the word mapDisplay the reaction diagram Show all sequences 2.7.7.602-C-methyl-D-erythritol 4-phosphate cytidylyltransferase drug development PfIspD enzyme inhibitor MMV008138 does not target the human IspD, reinforcing MMV008138 as a prototype of a distinct class of species-selective IspD-targeting antimalarial agents
Show all pathways known for 2.7.7.60Display the word mapDisplay the reaction diagram Show all sequences 2.7.7.602-C-methyl-D-erythritol 4-phosphate cytidylyltransferase drug development the methyl erythritol phosphate (MEP) pathway, including enzyme MEP cytidylyltransferase (IspD), represents an attractive series of targets for antibiotic design, considering each enzyme of the pathway is both essential and has no human homologues
Show all pathways known for 2.3.1.230Display the word mapDisplay the reaction diagram Show all sequences 2.3.1.2302-heptyl-4(1H)-quinolone synthase drug development the enzyme PqsBC is a potential drug target
Show all pathways known for 2.3.3.13Display the word mapDisplay the reaction diagram Show all sequences 2.3.3.132-isopropylmalate synthase drug development the enzyme is required for the proliferation of Mycobacterium tuberculosis and is also indispensable for its survival during the latent phase of infection. It is absent in humans and is widely regarded as one of the validated drug targets against Tuberculosis
Show all pathways known for 2.3.3.5Display the word mapDisplay the reaction diagram Show all sequences 2.3.3.52-methylcitrate synthase drug development androstenedione is an important steroid medicine intermediate that is obtained via the degradation of phytosterols by mycobacteria. The production process of androstenedione is mainly the degradation of the phytosterol aliphatic side chain, which is accompanied by the production of propionyl CoA. Excessive accumulation of intracellular propionyl-CoA produces a toxic effect in mycobacteria, which restricts the improvement of production efficiency. Biotransformation at low nitrogen levels can be improved by enhancing the methylcitrate cycle with transcriptional regulators PrpR and GlnR of Mycobacterium neoaurum
Show all pathways known for 2.3.3.5Display the word mapDisplay the reaction diagram Show all sequences 2.3.3.52-methylcitrate synthase drug development the fungi-specific 2-methylcitrate cycle is responsible for detoxifying propionyl-CoA, a toxic metabolite produced as the fungus breaks down proteins and amino acids. The enzyme responsible for this detoxification is 2-methylcitrate synthase (mcsA) and is a potential candidate for the design of new anti-fungals
Show all pathways known for 1.1.1.51Display the word mapDisplay the reaction diagram Show all sequences 1.1.1.513(or 17)beta-hydroxysteroid dehydrogenase drug development the steroidogenic enzyme 17beta-hydroxysteroid dehydrogenase type 3 (17beta-HSD3) is a therapeutic target in the management of androgen-sensitive diseases such as prostate cancer and benign prostate hyperplasia
Show all pathways known for 4.1.99.12Display the word mapDisplay the reaction diagram Show all sequences 4.1.99.123,4-dihydroxy-2-butanone-4-phosphate synthase drug development the enzyme is a target in antimicrobial inhibitor development, structure-based inhibitor design
Show all pathways known for 4.1.99.12Display the word mapDisplay the reaction diagram Show all sequences 4.1.99.123,4-dihydroxy-2-butanone-4-phosphate synthase drug development the enzyme is an attractive target for antibiotics, design of mechanism-based inhibitors
Show all pathways known for 4.1.99.12Display the word mapDisplay the reaction diagram Show all sequences 4.1.99.123,4-dihydroxy-2-butanone-4-phosphate synthase drug development the enzyme is a potential anti-infective target in the pathogenic yeast
Show all pathways known for 4.2.1.10Display the word mapDisplay the reaction diagram Show all sequences 4.2.1.103-dehydroquinate dehydratase drug development absence of the shikimate patway from humans makes the enzymes of this pathway potential drug targets
Show all pathways known for 4.2.1.10Display the word mapDisplay the reaction diagram Show all sequences 4.2.1.103-dehydroquinate dehydratase drug development the absence of DHQD in humans and its essentiality in many pathogenic bacteria make the enzyme a target for the development of nontoxic antimicrobials and design of type I DHQD inhibiting molecules
Show all pathways known for 4.2.1.10Display the word mapDisplay the reaction diagram Show all sequences 4.2.1.103-dehydroquinate dehydratase drug development the enzyme is an attractive target for the development of new antimicrobials and herbicides
Show all pathways known for 4.2.3.4Display the word mapDisplay the reaction diagram Show all sequences 4.2.3.43-dehydroquinate synthase drug development potential antibiotic target
Show all pathways known for 4.2.3.4Display the word mapDisplay the reaction diagram Show all sequences 4.2.3.43-dehydroquinate synthase drug development potential target for new antimicrobial agents, anti-parasitic agents and herbicides
Show all pathways known for 1.13.11.6Display the word mapDisplay the reaction diagram Show all sequences 1.13.11.63-hydroxyanthranilate 3,4-dioxygenase drug development the enzyme is a a potential target in treating numerous disorders related to the concentration of quinolinic acid, the kynurenine pathway product
Show all pathways known for 1.13.11.6Display the word mapDisplay the reaction diagram Show all sequences 1.13.11.63-hydroxyanthranilate 3,4-dioxygenase drug development the enzyme is a target for pharmacological downregulation because it is involved in formation of quinolinic acid, a highly potent excitotoxin implicated in a number of neurodegenerative conditions
Show all pathways known for 1.14.15.30Display the word mapDisplay the reaction diagram Show all sequences 1.14.15.303-ketosteroid 9alpha-monooxygenase drug development the enzyme can be a target for inhibition in treatment of tuberculosis
Show all pathways known for 1.1.1.100Display the word mapDisplay the reaction diagram Show all sequences 1.1.1.1003-oxoacyl-[acyl-carrier-protein] reductase drug development the enzyme has no isoforms and thus is a good target for inhibitor design
Show all pathways known for 1.1.1.100Display the word mapDisplay the reaction diagram Show all sequences 1.1.1.1003-oxoacyl-[acyl-carrier-protein] reductase drug development FabG is the antibacteria target of maple leaf extracts and tannic acid, and both reversible and irreversible inhibitions of FabG are important for the antibacterial effect
Show all pathways known for 1.1.1.100Display the word mapDisplay the reaction diagram Show all sequences 1.1.1.1003-oxoacyl-[acyl-carrier-protein] reductase drug development galangal extract inhibits FabG, thereby displaying antibacterial ability
Show all pathways known for 2.5.1.19Display the word mapDisplay the reaction diagram Show all sequences 2.5.1.193-phosphoshikimate 1-carboxyvinyltransferase drug development differential inhibition of class I and class II EPSPS by tetrahedral reaction intermediate-analogues possibly due to alteration of open-close transition during catalysis and/or upon inhibitor binding but not due to energy differences during complex formation
Show all pathways known for 2.5.1.19Display the word mapDisplay the reaction diagram Show all sequences 2.5.1.193-phosphoshikimate 1-carboxyvinyltransferase drug development more experimental data needed for effective structure-based drug design
Show all pathways known for 2.5.1.19Display the word mapDisplay the reaction diagram Show all sequences 2.5.1.193-phosphoshikimate 1-carboxyvinyltransferase drug development protonated enolpyruvylshikimate 3-phosphate (cation) intermediate as potential target for inhibitor design
Display the word mapDisplay the reaction diagram Show all sequences 1.1.1.3573alpha-hydroxysteroid 3-dehydrogenase drug development testosterone is converted to 5alpha-dihydrotestosterone, which is present at high concentrations in patients with castration resistant prostate cancer (CRPC). Inhibition of 17beta-HSD5 is therefore considered to be a promising therapy for treating CRPC. High-throughput inhibitor screening, overview
Show all pathways known for 1.1.1.213Display the word mapDisplay the reaction diagram Show all sequences 1.1.1.2133alpha-hydroxysteroid 3-dehydrogenase (Re-specific) drug development the enzyme is a target for treatment of chronic pain in neuropathic diseases, overview
Show all pathways known for 1.1.1.213Display the word mapDisplay the reaction diagram Show all sequences 1.1.1.2133alpha-hydroxysteroid 3-dehydrogenase (Re-specific) drug development 2'-hydroxyflavanone may be useful for clinical therapy of malignancies where AKR1C3 is overexpressed like in prostate and breast cancer
Display the word mapDisplay the reaction diagram Show all sequences 1.1.1.503alpha-hydroxysteroid 3-dehydrogenase (Si-specific) drug development the enzyme is a target for treatment of chronic pain in neuropathic diseases, overview
Show all pathways known for 1.3.8.2Display the word mapDisplay the reaction diagram Show all sequences 1.3.8.24,4'-diapophytoene desaturase (4,4'-diapolycopene-forming) drug development the enzyme CrtN is an attractive and druggable target for fighting pigmented Staphylococcus aureus infections
Show all pathways known for 2.7.1.148Display the word mapDisplay the reaction diagram Show all sequences 2.7.1.1484-(cytidine 5'-diphospho)-2-C-methyl-D-erythritol kinase drug development enzyme is a target for antimicrobial drug development
Show all pathways known for 2.7.1.148Display the word mapDisplay the reaction diagram Show all sequences 2.7.1.1484-(cytidine 5'-diphospho)-2-C-methyl-D-erythritol kinase drug development potential target for anti-infective drugs
Show all pathways known for 2.7.1.148Display the word mapDisplay the reaction diagram Show all sequences 2.7.1.1484-(cytidine 5'-diphospho)-2-C-methyl-D-erythritol kinase drug development enzymes of the MEP pathway represent potential targets for the generation of selective antibacterial, antimalarial and herbicidal molecules
Show all pathways known for 6.2.1.12Display the word mapDisplay the reaction diagram Show all sequences 6.2.1.124-coumarate-CoA ligase drug development the enzyme is a target for developing effective plant growth inhibitors, overview
Display the word mapDisplay the reaction diagram Show all sequences 2.4.1.1524-galactosyl-N-acetylglucosaminide 3-alpha-L-fucosyltransferase drug development development of a high-throughput screening system for identification of FucT-VII inhibitors, which could have anti-inflammatory or anti-metastatic potential, utilizing scintillation proximity assay with fetuin-coated beads, overview
Display the word mapDisplay the reaction diagram Show all sequences 2.4.1.1524-galactosyl-N-acetylglucosaminide 3-alpha-L-fucosyltransferase drug development fucosyltransferase VII is a very promising drug target for treatment of inflammatory skin diseases
Display the word mapDisplay the reaction diagram Show all sequences 2.4.1.1524-galactosyl-N-acetylglucosaminide 3-alpha-L-fucosyltransferase drug development FucT-VII and the E- and P-selectin pathways may prove a fruitful therapeutic target in the prevention or treatment of atherosclerosis
Show all pathways known for 1.17.1.8Display the word mapDisplay the reaction diagram Show all sequences 1.17.1.84-hydroxy-tetrahydrodipicolinate reductase drug development enzyme is a potential target for new antimicrobial and herbicidal compounds
Show all pathways known for 4.3.3.7Display the word mapDisplay the reaction diagram Show all sequences 4.3.3.74-hydroxy-tetrahydrodipicolinate synthase drug development DHDPS is a potential antibiotic target
Show all pathways known for 4.3.3.7Display the word mapDisplay the reaction diagram Show all sequences 4.3.3.74-hydroxy-tetrahydrodipicolinate synthase drug development the allosteric binding site of DHDPS may be a good starting point for development of an inhibitor specific to Neisseria meningitidis
Show all pathways known for 4.3.3.7Display the word mapDisplay the reaction diagram Show all sequences 4.3.3.74-hydroxy-tetrahydrodipicolinate synthase drug development the intracellular enzyme dihydrodipicolinate synthase a potential drug target because it is essential for the growth of bacteria while it is absent in humans
Show all pathways known for 4.3.3.7Display the word mapDisplay the reaction diagram Show all sequences 4.3.3.74-hydroxy-tetrahydrodipicolinate synthase drug development the enzyme is a bona fide drug target for treatment of the Crown Gall disease on crops caused by Agrobacterium tumefaciens, rational design of pesticide agents
Show all pathways known for 4.3.3.7Display the word mapDisplay the reaction diagram Show all sequences 4.3.3.74-hydroxy-tetrahydrodipicolinate synthase drug development the enzyme is an attractive target for rational antibiotic and herbicide design
Show all pathways known for 4.3.3.7Display the word mapDisplay the reaction diagram Show all sequences 4.3.3.74-hydroxy-tetrahydrodipicolinate synthase drug development the enzyme is an attractive target for the design and synthesis of herbicides and antibiotics
Show all pathways known for 4.3.3.7Display the word mapDisplay the reaction diagram Show all sequences 4.3.3.74-hydroxy-tetrahydrodipicolinate synthase drug development the enzyme is a promising antibiotic target
Show all pathways known for 4.3.3.7Display the word mapDisplay the reaction diagram Show all sequences 4.3.3.74-hydroxy-tetrahydrodipicolinate synthase drug development the enzyme is a target for antibiotics
Show all pathways known for 4.3.3.7Display the word mapDisplay the reaction diagram Show all sequences 4.3.3.74-hydroxy-tetrahydrodipicolinate synthase drug development the enzyme is an anti-cholera target
Show all pathways known for 1.14.13.2Display the word mapDisplay the reaction diagram Show all sequences 1.14.13.24-hydroxybenzoate 3-monooxygenase drug development p-hydroxybenzoate hydroxylase (PobA) from Pseudomonas putida is a possible drug target to combat tetracycline resistance, in complex with flavin adenine dinucleotide (FAD)
Show all pathways known for 1.13.11.27Display the word mapDisplay the reaction diagram Show all sequences 1.13.11.274-hydroxyphenylpyruvate dioxygenase drug development 4-hydroxyphenylpyruvate dioxygenase (HPPD), an essential enzyme in tyrosine catabolism, is an important target for treating type I tyrosinemia
Show all pathways known for 1.13.11.27Display the word mapDisplay the reaction diagram Show all sequences 1.13.11.274-hydroxyphenylpyruvate dioxygenase drug development 4-hydroxyphenylpyruvate dioxygenase is one of the most promising target sites for herbicide discovery
Show all pathways known for 1.13.11.27Display the word mapDisplay the reaction diagram Show all sequences 1.13.11.274-hydroxyphenylpyruvate dioxygenase drug development plant 4-hydroxyphenylpyruvate dioxygenase (HPPD) is the molecular target for development of specific inhibitors
Show all pathways known for 1.13.11.27Display the word mapDisplay the reaction diagram Show all sequences 1.13.11.274-hydroxyphenylpyruvate dioxygenase drug development the enzyme is a target for inhibitor and herbicide development
Results 1 - 100 of 1463 > >>